Drug Trial Radar · NCT02606305
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 20, 2026Latest source record: Jun 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
264
Actual
Start
Mar 2, 2016
Primary completion
Mar 12, 2021
Study completion Mar 12, 2021
Sponsor
- Lead sponsor
- ImmunoGen, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study comprises a Dose Escalation phase followed by a Dose Expansion phase. Dose Escalation part of the study will assess the safety and tolerability and determine the maximum tolerated dose (MTD) as the recommended Phase 2 (RP2D) dose for each regimen. Participants will be assigned to one of the 4 regimens in Dose Escalation phase: Regimen A: mirvetuximab soravtansine administered with bevacizumab; Regimen B: mirvetuximab soravtansine administered with carboplatin; Regimen C: mirvetuximab soravtansine administered with pegylated liposomal doxorubicin; or Regimen D: mirvetuximab soravtansine administered with pembrolizumab. Dose Expansion of the study will further assess safety, tolerability and preliminary anti-tumor activity of mirvetuximab soravtansine. A Dose Expansion phase is planned for Regimen A and Regimen D and will open pending Sponsor decision; participants enrolled in the Dose Expansion phase will receive study treatment at the MTD or RP2D determined during Dose Escalation. For Regimen A, participants in the Dose Expansion phase may be enrolled according to prior exposure to bevacizumab into 3 Dose Expansion Cohorts as follows: 1) Dose Expansion Cohort 1: bevacizumab naïve; 2) Dose Expansion Cohort 2: bevacizumab pretreated; and 3) Dose Expansion Cohort 3: one to three prior treatments, one of which could have been bevacizumab. A triplet Regimen (Regimen E: mirvetuximab soravtansine + bevacizumab + carboplatin) will be opened to evaluate the safety and tolerability and to assess any early signs of activity in participants dosed with the combination regimen. All mirvetuximab soravtansine doses were calculated according to adjusted ideal body weight.
Conditions
- Epithelial Ovarian Cancer
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
Interventions
Mirvetuximab soravtansineDrug
BevacizumabDrug
CarboplatinDrug
Pegylated Liposomal DoxorubicinDrug
PembrolizumabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to 30 days after last dose of study drug (maximum exposure: 238.3 weeks)
- Dose Expansion (Regimens A and D) and Triplet (Regimen E): Objective Response Rate (ORR); Percentage of Participants With Confirmed Response, as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From first dose of study drug until first CR or PR (maximum exposure: 238.3 weeks)
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
University of California at Los Angeles
Los Angeles, California
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
City of Hope
Reno, Nevada
The Ohio State University
Hilliard, Ohio
Peggy and Charles Stephenson Oklahoma Cancer Center
Oklahoma City, Oklahoma
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Universitaire Ziekenhuizen (UZ) Leuven - Gasthuisberg - Leuvens Kankerinstituut
Leuven, Belgium
Centre Hospitalier de l'universite de Montreal (CHUM)
Montreal, Canada
McGill University Health Center
Montreal, Canada
Hospital Vall D'Hebron
Barcelona, Spain
MD Anderson
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.